Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 6/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12207611 | 0.86 | CYP19A1 (0.40) | TSHRKMT2AGSK3BBACE1CYP19A1 | |
| SCHEMBL4503689 | 0.80 | TAAR1 (0.47) | TSHRKMT2ABACE1CYP19A1TAAR1 | |
| SCHEMBL13712700 | 0.77 | TSHR (0.43) | TSHRKMT2ABACE1BRD4CYP19A1 | |
| SCHEMBL4148110 | 0.76 | GSK3B (0.48) | TSHRKMT2AGSK3B | |
| Bromide SCHEMBL11626764 | 0.75 | MEN1 (0.44) | TSHRKMT2ANOS3BRD4NOS2 | |
| SCHEMBL7857600 | 0.70 | CYP19A1 (0.37) | TSHRKMT2ANOS3BACE1NOS2 | |
| SCHEMBL14959525 | 0.70 | BRD4 (0.67) | TSHRKMT2ABRD4 | |
| SCHEMBL11182534 | 0.68 | ALPL (0.56) | TSHRKMT2ANOS3NOS2 | |
| Phensuximide SCHEMBL35334 | 0.67 | KMT2A (1.00) | TSHRKMT2ABRD4CYP19A1 | |
| Phensuximide SCHEMBL35333 | 0.67 | KMT2A (1.00) | TSHRKMT2ABRD4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | claimed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101084199-A | Substituted amino-compounds and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | TSHR 4794/4885KMT2A 2653/4885GSK3B 124/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | TSHR 4479/4885KMT2A 2723/4885GSK3B 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.